Literature DB >> 11788980

Estimation of the transition matrix of a discrete-time Markov chain.

Bruce A Craig1, Peter P Sendi.   

Abstract

Discrete-time Markov chains have been successfully used to investigate treatment programs and health care protocols for chronic diseases. In these situations, the transition matrix, which describes the natural progression of the disease, is often estimated from a cohort observed at common intervals. Estimation of the matrix, however, is often complicated by the complex relationship among transition probabilities. This paper summarizes methods to obtain the maximum likelihood estimate of the transition matrix when the cycle length of the model coincides with the observation interval, the cycle length does not coincide with the observation interval, and when the observation intervals are unequal in length. In addition, the bootstrap is discussed as a method to assess the uncertainty of the maximum likelihood estimate and to construct confidence intervals for functions of the transition matrix such as expected survival. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 11788980     DOI: 10.1002/hec.654

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  17 in total

Review 1.  Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Authors:  Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven
Journal:  Nat Rev Neurol       Date:  2017-01-13       Impact factor: 42.937

2.  Inter-DRG resource dynamics in a prospective payment system: a stochastic kernel approach.

Authors:  Anurag Sharma
Journal:  Health Care Manag Sci       Date:  2009-03

3.  Using Markov Chains to predict the natural progression of diabetic retinopathy.

Authors:  Priyanka Srikanth
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

4.  Changing Cycle Lengths in State-Transition Models: Challenges and Solutions.

Authors:  Jagpreet Chhatwal; Suren Jayasuriya; Elamin H Elbasha
Journal:  Med Decis Making       Date:  2016-07-01       Impact factor: 2.583

5.  Evaluation of a method for fitting a semi-Markov process model in the presence of left-censored spells using the Cardiovascular Health Study.

Authors:  Liming Cai; Nathaniel Schenker; James Lubitz; Paula Diehr; Alice Arnold; Linda P Fried
Journal:  Stat Med       Date:  2008-11-20       Impact factor: 2.373

6.  HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011.

Authors:  Bohdan Nosyk; Jeong Min; Viviane D Lima; Benita Yip; Robert S Hogg; Julio S G Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

7.  Assessment of possible impact of a health promotion program in Korea from health risk trends in a longitudinally observed cohort.

Authors:  J Park; Sh Jee; Dw Edington
Journal:  Popul Health Metr       Date:  2004-11-11

8.  UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.

Authors:  Jacqueline Palace; Thomas Bregenzer; Helen Tremlett; Joel Oger; Feng Zhu; Fheng Zhu; Mike Boggild; Martin Duddy; Charles Dobson
Journal:  BMJ Open       Date:  2014-01-17       Impact factor: 2.692

9.  Markov chain evaluation of acute postoperative pain transition states.

Authors:  Patrick J Tighe; Matthew Bzdega; Roger B Fillingim; Parisa Rashidi; Haldun Aytug
Journal:  Pain       Date:  2016-03       Impact factor: 7.926

10.  Modeling the transmission of community-associated methicillin-resistant Staphylococcus aureus: a dynamic agent-based simulation.

Authors:  Charles M Macal; Michael J North; Nicholson Collier; Vanja M Dukic; Duane T Wegener; Michael Z David; Robert S Daum; Philip Schumm; James A Evans; Jocelyn R Wilder; Loren G Miller; Samantha J Eells; Diane S Lauderdale
Journal:  J Transl Med       Date:  2014-05-12       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.